FDA Policy Power Challenged In House Examination Of Untitled Letters
This article was originally published in The Rose Sheet
Executive Summary
Oversight and Investigations Subcommittee Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours. The Energy and Commerce Committee is examining whether the agency's use of untitled letters is “fair, effective and efficient in gaining compliance,” he says.